Medline (NASDAQ:MDLN) Stock Price Target Raised at Leerink Partners

Posted by Brian Himes on Nov 6th, 2026

Medline (NASDAQ:MDLN – Free Report) had its price objective hoisted by Leerink Partners from $43.00 to $46.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft set a $37.00 price target on shares of Medline and gave the company a “hold” rating in a report on Thursday, August 6th. Robert W. Baird set a $42.00 target price on shares of Medline in a research report on Thursday, August 6th. Barclays reduced their price target on shares of Medline from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 9th. Zacks Research lowered Medline from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Finally, Bank of America decreased their price objective on Medline from $53.00 to $46.00 in a report on Thursday, August 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.08.

Read Our Latest Analysis on Medline

Medline Trading Down 1.5%

Medline stock opened at $39.76 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. The company has a market capitalization of $52.27 billion and a price-to-earnings ratio of 33.35. Medline has a one year low of $31.37 and a one year high of $50.88. The company’s fifty day moving average price is $34.68 and its two-hundred day moving average price is $39.51.

Medline (NASDAQ:MDLN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.22% and a net margin of 1.84%. On average, analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Activity at Medline

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of Medline stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the completion of the transaction, the insider directly owned 16,453,806 shares of the company’s stock, valued at $576,705,900.30. This trade represents a 11.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 7,948,676 shares of company stock valued at $281,805,137. 0.81% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medline

Large investors have recently bought and sold shares of the business. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Medline by 233.3% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock valued at $222,500,000 after purchasing an additional 3,500,000 shares during the period. Bessemer Group Inc. increased its stake in shares of Medline by 39,404.0% in the 1st quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after acquiring an additional 3,495,136 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Medline by 30,255.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock valued at $94,353,000 after acquiring an additional 2,691,529 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Medline during the second quarter valued at approximately $40,430,000. Finally, Janus Henderson Group PLC increased its stake in Medline by 8.4% in the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock valued at $506,546,000 after purchasing an additional 887,240 shares in the last quarter.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

Positive Sentiment: Medline reported third-quarter EPS of $0.44, above the $0.32 consensus, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 results
Positive Sentiment: Several analysts raised price targets and maintained bullish ratings: UBS to $49, Citi to $47, and Leerink Partners to $46; BTIG reaffirmed Buy with a $55 target. These actions signal continued confidence in the stock’s potential. Read More., Read More., Read More., Read More.
Positive Sentiment: Medline plans to raise prices in 2027 to help offset inflation, and reports cited a $1 billion share-buyback plan—both potential supports for financial performance and shareholder returns. Pricing and Q3 results
Negative Sentiment: Despite the EPS beat, one report said quarterly profit fell, while Medline reaffirmed its full-year adjusted EBITDA outlook rather than raising it. That may have tempered the positive reaction to the results. Q3 profit and outlook report
Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to alleged product-quality issues. This is an allegation and investigation announcement, not a finding of wrongdoing, but it could add uncertainty for investors. Investigation announcement

Medline Company Profile

(Get Free Report)

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.